Premium
Incidence of cutaneous adverse events after exposure to tenofovir–emtricitabine in HIV ‐uninfected vs HIV ‐infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program
Author(s) -
Kosche C.,
Para A.,
Brieva J.,
West D.P.,
Palella F.J.,
Nardone B.
Publication year - 2019
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.15799
Subject(s) - emtricitabine , medicine , incidence (geometry) , pharmacovigilance , family medicine , population , human immunodeficiency virus (hiv) , adverse effect , dermatology , antiretroviral therapy , viral load , environmental health , physics , optics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom